-
Company Profile
Enliven Therapeutics Inc – Company Profile
Enliven Therapeutics Inc (Enliven Therapeutics), formerly a Imara Inc, is a clinical-stage precision oncology company that discovers and develops small molecule kinase inhibitors. The company product pipeline includes ELVN- 001 and ELVN- 002. Its product treats chronic myeloid leukemia (CML), non-small cell lung cancer (NSCLC) and solid tumors. Enliven Therapeutics pipeline program includes BCR-ABL and HER2 which carries out gene fusion, oncogenic, small molecule inhibitors and HER2 mutations including exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC)....
Add to Basket -
Product Insights
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. The Nuclear Factor Erythroid 2 Related Factor 2 - Drugs...
-
Product Insights
Thalassemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite, and jaundice. Treatment includes blood transfusions and bone marrow transplants. The Thalassemia Drugs in Development market research report provides an overview of the Thalassemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of...
-
Product Insights
Congestive Heart Failure (Heart Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Congestive heart failure (heart failure) report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure...